亚太药业 (002370.SZ) Latest Company News

Sep 2, 2026, 08:12 UTC
Zhuang Wei transferred his 39.96% partnership interest in Zhejiang Xinghao Holding Partnership to Qiu Zhongxun, and the business registration change has been completed.
Source:
- finance.sina.cn
Aug 18, 2026, 02:32 UTC
Yatai Pharmaceutical's wholly-owned subsidiary Zhejiang Yatai Lizhong Holding Co., Ltd. and Meiruida Health Investment (Wuhan) Partnership (Limited Partnership) jointly invested to establish Zhejiang Xingcui Biotechnology Co., Ltd., with a registered capital of 20 million yuan and legal representative Cheng Nana.
Source:
- finance.sina.cn
Aug 11, 2026, 10:58 UTC
Yatai Pharmaceutical completed a share buyback totaling 19.998 million yuan, repurchasing 3.3445 million shares (0.45% of total shares) for future equity incentives or employee stock ownership plans.
Source:
- finance.sina.cn
Jul 31, 2026, 09:09 UTC
Zhejiang Yatai Pharmaceutical Co., Ltd. announced that its spironolactone tablet 25mg specification passed the generic drug quality and efficacy consistency evaluation by the National Medical Products Administration and received the drug supplementary application approval notice.
Source:
- finance.sina.cn
Jul 21, 2026, 09:37 UTC
Yatai Pharmaceutical's actual controller and chairman Qiu Zhongxun proposed a share buyback of 10-20 million yuan, to be funded by internal and/or self-raised funds, for employee stock ownership or equity incentives.
Source:
Jul 7, 2026, 08:29 UTC
Yatai Pharmaceutical's subsidiary Yatai Lizhong subscribed to 30% of the expanded fund shares of Jiaxing Yuyan with 30 million yuan of its own funds, completed industrial and commercial registration, and the fund completed the change filing with the Asset Management Association of China.
Source:
- finance.sina.cn

002370.SZ

Zhuang Wei transferred his 39.96% partnership interest in Zhejiang Xinghao Holding Partnership to Qiu Zhongxun, and the business registration change has been completed.

Yatai Pharmaceutical completed a share buyback totaling 19.998 million yuan, repurchasing 3.3445 million shares (0.45% of total shares) for future equity incentives or employee stock ownership plans.

Zhejiang Yatai Pharmaceutical Co., Ltd. announced that its spironolactone tablet 25mg specification passed the generic drug quality and efficacy consistency evaluation by the National Medical Products Administration and received the drug supplementary application approval notice.

Yatai Pharmaceutical's actual controller and chairman Qiu Zhongxun proposed a share buyback of 10-20 million yuan, to be funded by internal and/or self-raised funds, for employee stock ownership or equity incentives.

Yatai Pharmaceutical's subsidiary Yatai Lizhong subscribed to 30% of the expanded fund shares of Jiaxing Yuyan with 30 million yuan of its own funds, completed industrial and commercial registration, and the fund completed the change filing with the Asset Management Association of China.